Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity: Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE next.
Stahl A, Nakanishi H, Lepore D, Wu WC, Azuma N, Jacas C, Vitti R, Athanikar A, Chu K, Iveli P, Zhao F, Leal S, Schlief S, Schmelter T, Miller T, Köfüncü E, Fielder A; FIREFLEYE next Study Group. Stahl A, et al. JAMA Netw Open. 2024 Apr 1;7(4):e248383. doi: 10.1001/jamanetworkopen.2024.8383. JAMA Netw Open. 2024. PMID: 38687481 Free PMC article. Clinical Trial.
Correction: Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.
Stahl A, Azuma N, Wu WC, Lepore D, Sukgen E, Nakanishi H, Mazela J, Leal S, Pieper A, Schlief S, Eissing T, Turner KC, Zhao A, Winkler J, Höchel J, Köfüncü E, Zimmermann T; FIREFLEYE Study Group. Stahl A, et al. Among authors: sukgen e. Eye (Lond). 2024 Jun;38(8):1599-1600. doi: 10.1038/s41433-024-02948-y. Eye (Lond). 2024. PMID: 38332376 Free PMC article. No abstract available.
Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.
Stahl A, Azuma N, Wu WC, Lepore D, Sukgen E, Nakanishi H, Mazela J, Leal S, Pieper A, Schlief S, Eissing T, Turner KC, Zhao A, Winkler J, Höchel J, Köfüncü E, Zimmermann T; FIREFLEYE Study Group. Stahl A, et al. Among authors: sukgen e. Eye (Lond). 2024 Jun;38(8):1444-1453. doi: 10.1038/s41433-023-02919-9. Epub 2024 Jan 10. Eye (Lond). 2024. PMID: 38200320 Free PMC article. Clinical Trial.
Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.
Stahl A, Sukgen EA, Wu WC, Lepore D, Nakanishi H, Mazela J, Moshfeghi DM, Vitti R, Athanikar A, Chu K, Iveli P, Zhao F, Schmelter T, Leal S, Köfüncü E, Azuma N; FIREFLEYE Study Group. Stahl A, et al. Among authors: sukgen ea. JAMA. 2022 Jul 26;328(4):348-359. doi: 10.1001/jama.2022.10564. JAMA. 2022. PMID: 35881122 Free PMC article. Clinical Trial.
Intraocular pressure in subjects with beta-thalassemia minor.
Keşkek ŞÖ, Keşkek NŞ, Ilgın G, Sukgen E. Keşkek ŞÖ, et al. Among authors: sukgen e. Arq Bras Oftalmol. 2019 May-Jun;82(3):220-224. doi: 10.5935/0004-2749.20190042. Epub 2019 Feb 25. Arq Bras Oftalmol. 2019. PMID: 30810618 Free article.
26 results